Products - Blood conditions | Topic

Showing 32 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 April 2025
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2025
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2025
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) (TA1029)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 January 2025
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 June 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 August 2025
Suspected sepsis: recognition, diagnosis and early management
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
18 July 2025
Expected publication date:
19 November 2025
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 December 2025
ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]
Status:
Topic selection
Programme:
Health technology evaluation
Expected publication date:
TBC
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olezarsen for treating familial chylomicronaemia syndrome [TSID11993]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avapritinib for treating moderate to severe symptoms of indolent systemic mastocytosis [ID12202]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Blood conditions Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 32 products

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)

Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) (TA1029)

Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

Suspected sepsis: recognition, diagnosis and early management

Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]

Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]

Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]

Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]

Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312

Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]

Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]

MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]

Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]

Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994

Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]

Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]

Olezarsen for treating familial chylomicronaemia syndrome [TSID11993]

Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]

Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]

Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]

Avapritinib for treating moderate to severe symptoms of indolent systemic mastocytosis [ID12202]

Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

Blood conditions Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 32 products

Product type
1 selected

New and updated
1 selected